SIGA Technologies  
Worldwide
 
Overview
 

Company News

SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat
SIGA Technologies (April 25, 2016)
PharmAthene Reports Court Approval of SIGA Reorganization Plan to Exit from Bankruptcy
PharmAthene (April 13, 2016)
SIGA Emerges from Chapter 11 Bankruptcy Protection
SIGA Technologies (April 12, 2016)
SIGA Commences Clinical Study for Intravenous (IV) Formulation of TPOXX
SIGA Technologies (March 17, 2016)
SIGA Technologies Engages PiperJaffray as Financial Advisor
SIGA Technologies (March 15, 2016)

Displaying 5 out of a possible 242 unique stories.
Results Sorted By date


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile SIGA Technologies (SIGAQ) is a New York based pharmaceutical company focused on development of therapeutic solutions for some of the most lethal disease causing pathogens including Ebola & other dangerous viruses.

09 FEB 2016: Filed amended reorganization plan.
15 DEC 2015: Filed reorganization plan with U.S. bankruptcy court to exit from bankruptcy.
17 SEP 2014: Received Bankruptcy Court approval of "first-day" motions.
16 SEP 2014: Company filed a voluntary petition for relief under Chapter 11 of the US Bankruptcy Code in the US Bankruptcy Court.
Listed or Private Company Listed
Company Classification Biotechnology
Country USA
Company Website Website
Technology Platform Profile
Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
11/08/2014 10 Aug: Company announces that the Delaware Court of Chancery issued a memorandum opinion on 8 Aug ordering SIGA to pay PharmAthene damages for the value of its lost profits from SIGA's smallpox antiviral, tecovirimat. 90 -38.7% -57

EvaluatePharma® Coverage of Marketed and Pipeline Products

Product Count
SIGA Technologies 1 22

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


Register to access more FREE content:

  • 2011 Product Sales analysis
  • 2011 Pharmaceutical Sales
  • 2011 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now